![Transparency Market Researchが調査・発行した産業分析レポートです。HER2検査のグローバル市場（2023-2031年）：FISH法、二重プローブ、単一プローブ、発色in situハイブリダイゼーション（CISH）法、銀強化in situハイブリダイゼーション / HER2 Testing Market [Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization (CISH) & Silver-enhanced in situ hybridization] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031 / MRC2307A0223資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/report-contents-54.gif) | • レポートコード：MRC2307A0223 • 出版社/出版日：Transparency Market Research / 2023年5月 • レポート形態：英文、PDF、176ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の市場調査資料によると、世界のHER2検査市場規模は2023年の135.2百万ドルから2031年には259.4百万ドルへ上り、予想期間中、年平均7.3％拡大すると予測されています。本調査資料では、HER2検査の世界市場を調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要洞察、技術別（FISH法、二重プローブ、単一プローブ、発色in situハイブリダイゼーション（CISH）法、銀強化in situハイブリダイゼーション）分析、がん種類別（乳がん、胃がん）分析、エンドユーザー別（病院、診断研究所、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などについて明らかにしています。なお、本書に記載されている企業情報には、Abbott、Hoffmann-La Roche Ltd、Agilent Technologies, Inc.、Thermo Fisher Scientific, Inc.、Leica Biosystems (Danaher Corporation)、Empire Genomics, Inc. (Biocare Medical, LLC)、Bio-Genex Laboratories、Abnova Corporationなどが含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要洞察 ・世界のHER2検査市場規模：技術別 - FISH法における市場規模 - 二重プローブにおける市場規模 - 単一プローブにおける市場規模 - 発色in situハイブリダイゼーション（CISH）法における市場規模 - 銀強化in situハイブリダイゼーション法における市場規模 ・世界のHER2検査市場規模：がん種類別 - 乳がんにおける市場規模 - 胃がんにおける市場規模 ・世界のHER2検査市場規模：エンドユーザー別 - 病院における市場規模 - 診断研究所における市場規模 - その他エンドユーザーにおける市場規模 ・世界のHER2検査市場規模：地域別 - 北米のHER2検査市場規模 - ヨーロッパのHER2検査市場規模 - アジア太平洋のHER2検査市場規模 - 中南米のHER2検査市場規模 - 中東・アフリカのHER2検査市場規模 ・競争状況 |
HER2 Testing Market – Scope of Report
TMR’s report on the global HER2 Testing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global HER2 Testing market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global HER2 Testing market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the HER2 Testing market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global HER2 Testing market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global HER2 Testing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global HER2 Testing market.
The report delves into the competitive landscape of the global HER2 Testing market. Key players operating in the global HER2 Testing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global HER2 Testing market profiled in this report.
Key Questions Answered in Global HER2 Testing Market Report
• What is the sales/revenue generated by HER2 Testing across all regions during the forecast period?
• What are the opportunities in the global HER2 Testing market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
HER2 Testing Market – Research Objectives and Research Approach
The comprehensive report on the global HER2 Testing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global HER2 Testing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global HER2 Testing market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global HER2 Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global HER2 Testing Market Analysis and Forecasts, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Detailed Analysis of HER2 Expression in Gastric & Gastroesophageal Cancer
5.2. Breast and Gastric Cancer Prevalence & Incidence Rate globally with key countries
5.3. Regulatory Scenario
5.4. Key Industry Developments
5.5. Pipeline Analysis for Gastric Cancer
5.6. COVID-19 Pandemic Impact on Industry (Value Chain and Short-/Mid-/Long-term Impact)
6. Global HER2 Testing Market Analysis and Forecast, by Technique
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Technique, 2017-2031
6.3.1. Fluorescence in situ hybridization
6.3.2. Dual-probe
6.3.3. Single-probe
6.3.4. Chromogenic in situ hybridization (CISH)
6.3.5. Silver-enhanced in situ hybridization
6.4. Market Attractiveness, by Technique
7. Global HER2 Testing Market Analysis and Forecast, by Cancer Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Cancer Type, 2017-2031
7.3.1. Breast Cancer
7.3.2. Gastric Cancer
7.4. Market Attractiveness, by Cancer Type
8. Global HER2 Testing Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017-2031
8.3.1. Hospitals
8.3.2. Diagnostic Laboratories
8.3.3. Others
8.4. Market Attractiveness, by End-user
9. Global HER2 Testing Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Country/Region
10. North America HER2 Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Technique, 2017-2031
10.2.1. Fluorescence in situ hybridization
10.2.2. Dual-probe
10.2.3. Single-probe
10.2.4. Chromogenic in situ hybridization (CISH)
10.2.5. Silver-enhanced in situ hybridization
10.3. Market Value Forecast, by Cancer Type, 2017-2031
10.3.1. Breast Cancer
10.3.2. Gastric Cancer
10.4. Market Value Forecast, by End-user, 2017-2031
10.4.1. Hospitals
10.4.2. Diagnostic Laboratories
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Technique
10.6.2. By Cancer Type
10.6.3. By End-user
10.6.4. By Country
11. Europe HER2 Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Technique, 2017-2031
11.2.1. Fluorescence in situ hybridization
11.2.2. Dual-probe
11.2.3. Single-probe
11.2.4. Chromogenic in situ hybridization (CISH)
11.2.5. Silver-enhanced in situ hybridization
11.3. Market Value Forecast, by Cancer Type, 2017-2031
11.3.1. Breast Cancer
11.3.2. Gastric Cancer
11.4. Market Value Forecast, by End-user, 2017-2031
11.4.1. Hospitals
11.4.2. Diagnostic Laboratories
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Technique
11.6.2. By Cancer Type
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific HER2 Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Technique, 2017-2031
12.2.1. Fluorescence in situ hybridization
12.2.2. Dual-probe
12.2.3. Single-probe
12.2.4. Chromogenic in situ hybridization (CISH)
12.2.5. Silver-enhanced in situ hybridization
12.3. Market Value Forecast, by Cancer Type, 2017-2031
12.3.1. Breast Cancer
12.3.2. Gastric Cancer
12.4. Market Value Forecast, by End-user, 2017-2031
12.4.1. Hospitals
12.4.2. Diagnostic Laboratories
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Technique
12.6.2. By Cancer Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America HER2 Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Technique, 2017-2031
13.2.1. Fluorescence in situ hybridization
13.2.2. Dual-probe
13.2.3. Single-probe
13.2.4. Chromogenic in situ hybridization (CISH)
13.2.5. Silver-enhanced in situ hybridization
13.3. Market Value Forecast, by Cancer Type, 2017-2031
13.3.1. Breast Cancer
13.3.2. Gastric Cancer
13.4. Market Value Forecast, by End-user, 2017-2031
13.4.1. Hospitals
13.4.2. Diagnostic Laboratories
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Technique
13.6.2. By Cancer Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa HER2 Testing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Technique, 2017-2031
14.2.1. Fluorescence in situ hybridization
14.2.2. Dual-probe
14.2.3. Single-probe
14.2.4. Chromogenic in situ hybridization (CISH)
14.2.5. Silver-enhanced in situ hybridization
14.3. Market Value Forecast, by Cancer Type, 2017-2031
14.3.1. Breast Cancer
14.3.2. Gastric Cancer
14.4. Market Value Forecast, by End-user, 2017-2031
14.4.1. Hospitals
14.4.2. Diagnostic Laboratories
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Technique
14.6.2. By Cancer Type
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2022)
15.3. Company Profiles
15.3.1. Abbott
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. Hoffmann-La Roche Ltd
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Strategic Overview
15.3.3. Agilent Technologies, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Strategic Overview
15.3.4. Thermo Fisher Scientific, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Strategic Overview
15.3.5. Leica Biosystems (Danaher Corporation)
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Strategic Overview
15.3.6. Empire Genomics, Inc. (Biocare Medical, LLC)
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Strategic Overview
15.3.7. Bio-Genex Laboratories
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Abnova Corporation
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. Oxford Gene Technology IP Limited (Sysmex Corporation)
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
Table 01: Global HER2 Testing Market Size (US$ Mn) Forecast, by Technique, 2017-2031
Table 02: Global HER2 Testing Market Size (US$ Mn) Forecast, by Fluorescence in situ hybridization, 2017-2031
Table 03: Global HER2 Testing Market Size (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 04: Global HER2 Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 05: Global HER2 Testing Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America HER2 Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America HER2 Testing Market Size (US$ Mn) Forecast, by Technique, 2017-2031
Table 08: North America HER2 Testing Market size (US$ Mn) Forecast, by Fluorescence in situ hybridization, 2017-2031
Table 09: North America HER2 Testing Market Size (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 10: North America HER2 Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 11: Europe HER2 Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 12: Europe HER2 Testing Market Size (US$ Mn) Forecast, by Technique, 2017-2031
Table 13: Europe HER2 Testing Market Size (US$ Mn) Forecast, by Fluorescence in situ hybridization, 2017-2031
Table 14: Europe HER2 Testing Market Size (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 15: Europe HER2 Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 16: Asia-Pacific HER2 Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 17: Asia-Pacific HER2 Testing Market Size (US$ Mn) Forecast, by Technique, 2017-2031
Table 18: Asia-Pacific HER2 Testing Market Size (US$ Mn) Forecast, by Fluorescence in situ hybridization, 2017-2031
Table 19: Asia-Pacific HER2 Testing Market Size (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 20: Asia-Pacific HER2 Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Latin America HER2 Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 22: Latin America HER2 Testing Market Size (US$ Mn) Forecast, by Technique, 2017-2031
Table 23: Latin America HER2 Testing Market Size (US$ Mn) Forecast, by Fluorescence in situ hybridization, 2017-2031
Table 24: Latin America HER2 Testing Market Size (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 25: Latin America HER2 Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 26: Middle East & Africa HER2 Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 27: Middle East & Africa HER2 Testing Market Size (US$ Mn) Forecast, by Technique, 2017-2031
Table 28: Middle East & Africa HER2 Testing Market Size (US$ Mn) Forecast, by Fluorescence in situ hybridization, 2017-2031
Table 29: Middle East & Africa HER2 Testing Market Size (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 30: Middle East & Africa HER2 Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031